Skip to main content

Advertisement

SpringerLink
Log in

Medical Management of Peyronie’s Disease: a 2014 Update

  • MALE SEXUAL DYSFUNCTION AND DISORDERS (M KHERA AND SE ALTHOF, SECTION EDITORS)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Peyronie’s disease (PD) is a connective tissue disorder characterized by the development of dense fibrous collagen plaque deposits in the tunica albuginea of the penis, resulting in curvature of the erection and sexual dysfunction. It is both a physically and psychologically devastating disorder that remains a considerable therapeutic dilemma due to incomplete characterization of its pathophysiology and the paucity of randomized controlled trials. Along with an underlying genetic predisposition, numerous studies have implicated pro-inflammatory cascades and oxidative stress in the development of PD. Medical therapies targeting these pathways can be partially effective at decreasing or inhibiting plaque formation and symptoms of PD. Such therapies include the broad categories of oral medication and vitamin supplements, intralesional injections, and penile traction. The recent FDA approval for intralesional collagenase clostridium histolyticum provides a significant advancement in the medical treatment of PD. In addition to highlighting the latest data supporting intralesional collagenase clostridium histolyticum, this update aims to review the most current literature on all of the available options for medical treatment of PD and to provide a practical approach to the clinical management of PD in the office setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543–52. Systematic literature review comprising the most comprehensive guideline paper available for the evaluation and treatment of Peyronie’s disease.

    Article  PubMed  Google Scholar 

  2. Musitelli S, Bossi M, Jallous H. A brief historical survey of “Peyronie’s disease”. J Sex Med. 2008;5(7):1737–46.

    Article  PubMed  Google Scholar 

  3. Devine Jr CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(1):285–90.

    Article  PubMed  Google Scholar 

  4. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158(6):2284–90.

    Article  CAS  PubMed  Google Scholar 

  5. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol. 2005;2(6):291–7.

    Article  CAS  PubMed  Google Scholar 

  6. Bivalacqua TJ, Champion HC, Hellstrom WJ. Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie’s disease. Int J Impot Res. 2002;14(5):345–52.

    Article  CAS  PubMed  Google Scholar 

  7. Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5(9):2179–84.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7(3):1254–61.

    Article  PubMed  Google Scholar 

  9. Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, et al. Peyronie’s disease is associated with Paget’s disease of bone. J Bone Miner Res. 1997;12(6):929–34.

    Article  CAS  PubMed  Google Scholar 

  10. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie’s disease. J Urol. 2002;168(3):1075–9.

    Article  PubMed  Google Scholar 

  11. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115,8. discussion 2118.

    Article  Google Scholar 

  12. Scott WW, Scardino PL. A new concept in the treatment of Peyronie’s disease. South Med J. 1948;41(2):173–7.

    Article  CAS  PubMed  Google Scholar 

  13. Paulis G, Brancato T, D’Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, et al. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120–8.

    Article  CAS  PubMed  Google Scholar 

  14. Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie’s disease. Int J Impot Res. 2002;14(5):353–60.

    Article  CAS  PubMed  Google Scholar 

  15. Pryor JP, Farrell C. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol Med. 1983;9:41–5.

    Google Scholar 

  16. Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie’s disease. Int J Urol. 2006;13(3):244–7.

    Article  PubMed  Google Scholar 

  17. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.

    Article  CAS  PubMed  Google Scholar 

  18. Mukai K, Tokunaga A, Itoh S, Kanesaki Y, Ohara K, Nagaoka S, et al. Structure-activity relationship of the free-radical-scavenging reaction by vitamin E (alpha-, beta-, gamma-, delta-tocopherols) and ubiquinol-10: pH dependence of the reaction rates. J Phys Chem B. 2007;111(3):652–62.

    Article  CAS  PubMed  Google Scholar 

  19. Nohl H, Gille L, Kozlov AV. Antioxidant-derived prooxidant formation from ubiquinol. Free Radic Biol Med. 1998;25(6):666–75.

    Article  CAS  PubMed  Google Scholar 

  20. Choi HK, Pokharel YR, Lim SC, Han HK, Ryu CS, Kim SK, et al. Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol Appl Pharmacol. 2009;240(3):377–84.

    Article  CAS  PubMed  Google Scholar 

  21. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298–309.

    Article  CAS  PubMed  Google Scholar 

  22. Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/smad-dependent mechanism and downregulation of AAT1. J Sex Med. 2010;7(5):1787–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111,5. quiz 116.

    Article  Google Scholar 

  25. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010;106(2):240–8.

    Article  CAS  PubMed  Google Scholar 

  26. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229–44.

    Article  CAS  PubMed  Google Scholar 

  27. Levine LA. Current approach to the man with acute phase Peyronie’s disease—case presentation and discussion. J Sex Med. 2011;8(6):1556,8. quiz 1559.

    Article  Google Scholar 

  28. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24(2):239–45.

    PubMed  Google Scholar 

  29. Diegelmann RF. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Urol. 1997;157(1):298–302.

    Article  CAS  PubMed  Google Scholar 

  30. McCullough A. Penile change following radical prostatectomy: size, smooth muscle atrophy, and curve. Curr Urol Rep. 2008;9(6):492–9.

    Article  PubMed  Google Scholar 

  31. Kim H, Sohn DW, Kim SD, Hong SH, Suh HJ, Lee CB, et al. The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. Int J Impot Res. 2010;22(5):291–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7(4):262–76.

    Article  CAS  PubMed  Google Scholar 

  33. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472–7.

    Article  CAS  PubMed  Google Scholar 

  34. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190–5.

    Article  CAS  PubMed  Google Scholar 

  35. Chung E, Garcia F, Young LD, Solomon M, Brock GB. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol. 2013;189(1):380–4.

    Article  CAS  PubMed  Google Scholar 

  36. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–6.

    Article  CAS  PubMed  Google Scholar 

  37. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621,5. discussion 625-6.

    Article  Google Scholar 

  38. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–4.

    CAS  PubMed  Google Scholar 

  39. Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol. 1997;158(4):1395–9.

    Article  CAS  PubMed  Google Scholar 

  40. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–71.

    Article  CAS  PubMed  Google Scholar 

  41. Moskovic DJ, Alex B, Choi JM, Nelson CJ, Mulhall JP. Defining predictors of response to intralesional verapamil injection therapy for Peyronie’s disease. BJU Int. 2011;108(9):1485–9.

    Article  CAS  PubMed  Google Scholar 

  42. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94.

    Article  CAS  PubMed  Google Scholar 

  43. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl. 1999;20(4):444–8.

    CAS  PubMed  Google Scholar 

  44. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie’s disease: a pilot study. Br J Urol. 1997;79(1):40–2.

    Article  CAS  PubMed  Google Scholar 

  45. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie’s disease. Eur Urol. 1997;32(2):190–3.

    CAS  PubMed  Google Scholar 

  46. Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie’s disease. South Med J. 2004;97(1):42–6.

    Article  PubMed  Google Scholar 

  47. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8.

    Article  CAS  PubMed  Google Scholar 

  48. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207. This multicenter double-blind randomized controlled trial of collagenase injections for Peyronie’s Disease demonstrated effective reduction of dorsal penile curvature in mature plaques with excellent safety profile, and represented the pivotal study in the FDA approval of the drug.

    Article  CAS  PubMed  Google Scholar 

  49. Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res. 2011;23(4):142–5.

    Article  CAS  PubMed  Google Scholar 

  50. Dolmans GH, Werker PM, de Jong IJ, Nijman RJ, LifeLines Cohort Study, Wijmenga C, et al. WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. J Sex Med. 2012;9(5):1430–4.

    Article  CAS  PubMed  Google Scholar 

  51. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180–7.

    Article  PubMed  Google Scholar 

  52. Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–74.

    Article  CAS  PubMed  Google Scholar 

  53. Carson III C, Sadeghi-Nejad H, Smith T, Kaufman G, Gilbert K, Honig S. Integrated safety profile of collagenase clostridium histolyticum in clinical studies evaluating the treatment of Peyronie’s disease. J Urol. 2013;189(4, Supplement):e683.

    Article  Google Scholar 

  54. Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie’s disease: measured lengths and patient perceptions. J Sex Med. 2012;9(9):2396–403.

    Article  PubMed  Google Scholar 

  55. Molea G, Schonauer F, Blasi F. Progressive skin extension: clinical and histological evaluation of a modified procedure using Kirschner wires. Br J Plast Surg. 1999;52(3):205–8.

    Article  CAS  PubMed  Google Scholar 

  56. Sun JS, Hou SM, Hang YS, Liu TK, Lu KS. Ultrastructural studies on myofibrillogenesis and neogenesis of skeletal muscles after prolonged traction in rabbits. Histol Histopathol. 1996;11(2):285–92.

    CAS  PubMed  Google Scholar 

  57. Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE. 2002;2002(119):e6.

    Google Scholar 

  58. Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med. 2012;9(1):288–95.

    Article  CAS  PubMed  Google Scholar 

  59. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558–66.

    Article  PubMed  Google Scholar 

  60. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–73.

    Article  PubMed  Google Scholar 

  61. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–80.

    Article  PubMed  Google Scholar 

  62. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3(3):382,404. discussion 404-7.

    Article  Google Scholar 

  63. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140(4):1861–8.

    CAS  PubMed  Google Scholar 

  64. Nam HJ, Park HJ, Park NC. Does testosterone deficiency exaggerate the clinical symptoms of Peyronie’s disease? Int J Urol. 2011;18(11):796–800.

    Article  CAS  PubMed  Google Scholar 

  65. Cavallini G, Biagiotti G, Lo Giudice C. Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations. J Androl. 2012;33(3):381–8. Coupling of testosterone replacement with verapamil injections in appropriate patients is associated with improvements in plaque size and curvature.

    Article  CAS  PubMed  Google Scholar 

  66. Coward RM, Verges D, Smith AB, Carson CC. Testosterone deficiency is similarly prevalent among men presenting with either Peyronie’s disease or erectile dysfunction. J Sex Med. 2012;9 suppl 1:3–62.

    Google Scholar 

  67. Castiglione F, Hedlund P, Van der Aa F, Bivalacqua TJ, Rigatti P, Van Poppel H, et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol. 2013;63(3):551–60. Stem cell therapy represents a potential future therapeutic direction for the treatment of Peyronie’s disease.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Josip Vukina, Aaron C. Lentz, Ryan P. Smith, and Larry I. Lipshultz declare that they have no conflict of interest. Culley C. Carson has served as a consultant for and has received grant support and honoraria from Auxilium. Robert M. Coward has served as a consultant for American Medical Systems and has received grant support from the NIH and NICHD.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, University of North Carolina, 2113 Physicians Office Building, Campus Box 7235, Chapel Hill, NC, 27599-7235, USA

    Josip Vukina, Culley C. Carson & Robert M. Coward

  2. Division of Urologic Surgery, Duke University, 3480 Wake Forest Road Suite 506, Raleigh, NC, 27609, USA

    Aaron C. Lentz

  3. Department of Urology, University of Virginia, PO Box 800422, Charlottesville, VA, 22908-0422, USA

    Ryan P. Smith

  4. Baylor College of Medicine, 6624 Fannin Street Suite 1700, Houston, TX, 77030, USA

    Larry I. Lipshultz

Authors
  1. Josip Vukina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron C. Lentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan P. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Larry I. Lipshultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Culley C. Carson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert M. Coward
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert M. Coward.

Additional information

This article is part of the Topical Collection on Male Sexual Dysfunction and Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vukina, J., Lentz, A.C., Smith, R.P. et al. Medical Management of Peyronie’s Disease: a 2014 Update. Curr Sex Health Rep 6, 155–163 (2014). https://doi.org/10.1007/s11930-014-0021-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-014-0021-y

Keywords

Search

Navigation